<SEC-DOCUMENT>0000899243-18-013571.txt : 20180521
<SEC-HEADER>0000899243-18-013571.hdr.sgml : 20180521
<ACCEPTANCE-DATETIME>20180521163424
ACCESSION NUMBER:		0000899243-18-013571
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20180517
FILED AS OF DATE:		20180521
DATE AS OF CHANGE:		20180521

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Canaan Partners X LLC
		CENTRAL INDEX KEY:			0001673228
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37852
		FILM NUMBER:		18850078

	BUSINESS ADDRESS:	
		STREET 1:		2765 SAND HILL ROAD
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6508548092

	MAIL ADDRESS:	
		STREET 1:		2765 SAND HILL ROAD
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			CANAAN X L.P.
		CENTRAL INDEX KEY:			0001619859
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37852
		FILM NUMBER:		18850079

	BUSINESS ADDRESS:	
		STREET 1:		285 RIVERSIDE AVE.
		STREET 2:		SUITE 250
		CITY:			WESTPORT
		STATE:			CT
		ZIP:			06880
		BUSINESS PHONE:		203-855-0400

	MAIL ADDRESS:	
		STREET 1:		285 RIVERSIDE AVE.
		STREET 2:		SUITE 250
		CITY:			WESTPORT
		STATE:			CT
		ZIP:			06880

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protagonist Therapeutics, Inc
		CENTRAL INDEX KEY:			0001377121
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				980505495
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160
		BUSINESS PHONE:		(510) 474-0170

	MAIL ADDRESS:	
		STREET 1:		7707 GATEWAY BLVD., SUITE 140
		CITY:			NEWARK
		STATE:			CA
		ZIP:			94560-1160

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Therapeutics Inc
		DATE OF NAME CHANGE:	20130605

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Protagonist Inc
		DATE OF NAME CHANGE:	20061002
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2018-05-17</periodOfReport>

    <notSubjectToSection16>1</notSubjectToSection16>

    <issuer>
        <issuerCik>0001377121</issuerCik>
        <issuerName>Protagonist Therapeutics, Inc</issuerName>
        <issuerTradingSymbol>PTGX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001619859</rptOwnerCik>
            <rptOwnerName>CANAAN X L.P.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>285 RIVERSIDE AVENUE, SUITE 250</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>WESTPORT</rptOwnerCity>
            <rptOwnerState>CT</rptOwnerState>
            <rptOwnerZipCode>06880</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001673228</rptOwnerCik>
            <rptOwnerName>Canaan Partners X LLC</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>285 RIVERSIDE AVENUE, SUITE 250</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>WESTPORT</rptOwnerCity>
            <rptOwnerState>CT</rptOwnerState>
            <rptOwnerZipCode>06880</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2018-05-17</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>38968</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>6.0911</value>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2116552</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F2"/>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $5.90 - $6.46, inclusive.  The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
        <footnote id="F2">These shares are held directly by Canaan X L.P. (the &quot;Canaan Fund&quot;).  The sole general partner of the Canaan Fund is Canaan Partners X LLC (&quot;Canaan X&quot;, and together with the Canaan Fund, the &quot;Canaan Entities&quot;), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan X disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any.</footnote>
    </footnotes>

    <remarks>Exhibit 24 - Power of Attorney (incorporated by reference to the Power of Attorney filed as Exhibit 24 to the Form 3 filed by the Reporting Persons on August 10, 2016)</remarks>

    <ownerSignature>
        <signatureName>Canaan X L.P., By: Canaan Partners X LLC, its general partner, By: /s/ Janine MacDonald, Attorney-in-Fact</signatureName>
        <signatureDate>2018-05-21</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>Canaan Partners X LLC, By: /s/ Janine MacDonald, Attorney-in-Fact</signatureName>
        <signatureDate>2018-05-21</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
